Insider · CIK 0001836254
Ian Michael Estepan
cfoofficercoo
Files at SRPT (Sarepta Therapeutics, Inc.). First filing Dec 18, 2025, latest Dec 18, 2025.
Track record
Not enough history
Fewer than three past buys with six months of prices.
Median 6-month excess
-
after past buys, n = 0
Hit rate
-
past buys that beat the index over 6 months
Open-market trades
0 / 1
$0 bought, $294k sold
Where the trades landed
Last year at the company this insider has traded most, with each buy and sell on the bar it happened.
SRPT: Sarepta Therapeutics, Inc.
SRPTOct 9, 2026 · close 17.85
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value. Click a marked bar to open the signal.Charts by TradingView Lightweight Charts™
Signals
This insider’s open-market buys and sells, scored.
| Score | Company | Value | Holdings | Price context | Filed |
|---|---|---|---|---|---|
| 34Weak | SRPTsell Sarepta Therapeutics, Inc. | $294k 13,187 shares | -6% | +87% from low-83% from high |
Transactions
Every row this insider has filed, newest first.
| Date | Company | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|---|
| Sep 4, 2026 | SRPT Sarepta Therapeutics, Inc. | FTax withholding Common Stock | -24,799 | $22.22 | $551k | 177,184 | 34 d ago |
| Mar 11, 2026 | SRPT Sarepta Therapeutics, Inc. | FTax withholding Common Stock | -1,097 | $17.03 | $19k | 201,983 | Mar 13, 2026 |
| Mar 9, 2026 | SRPT Sarepta Therapeutics, Inc. | FTax withholding Common Stock | -1,036 | $16.95 | $18k | 203,663 | Mar 11, 2026 |
| Mar 9, 2026 | SRPT Sarepta Therapeutics, Inc. | FTax withholding Common Stock | -583 | $16.95 | $9,882 | 203,080 | Mar 11, 2026 |
| Mar 1, 2026 | SRPT Sarepta Therapeutics, Inc. | MOption exercise Common Stock | +8,125 | - | - | 208,875 | Mar 3, 2026 |
| Mar 2, 2026 | SRPT Sarepta Therapeutics, Inc. | FTax withholding Common Stock | -3,301 | $16.20 | $53k | 205,574 | Mar 3, 2026 |
| Mar 2, 2026 | SRPT Sarepta Therapeutics, Inc. | FTax withholding Common Stock | -875 | $16.20 | $14k | 204,699 | Mar 3, 2026 |
| Mar 1, 2026 | SRPT Sarepta Therapeutics, Inc. | MOption exercise Performance Stock Unitsderivative | -8,125 | $0.00 | $0 | 0 | Mar 3, 2026 |
| Feb 26, 2026 | SRPT Sarepta Therapeutics, Inc. | MOption exercise Common Stock | +2,069 | $13.71 | $28k | 195,369 | Mar 2, 2026 |
| Feb 26, 2026 | SRPT Sarepta Therapeutics, Inc. | MOption exercise Common Stock | +5,381 | $13.71 | $74k | 200,750 | Mar 2, 2026 |
| Feb 26, 2026 | SRPT Sarepta Therapeutics, Inc. | MOption exercise Stock Option (right to buy)derivative | -2,069 | $0.00 | $0 | 0 | Mar 2, 2026 |
| Feb 26, 2026 | SRPT Sarepta Therapeutics, Inc. | MOption exercise Stock Option (right to buy)derivative | -5,381 | $0.00 | $0 | 0 | Mar 2, 2026 |
| Feb 25, 2026 | SRPT Sarepta Therapeutics, Inc. | AGrant or award Performance Stock Unitsderivative | +1,875 | - | - | 8,125 | Feb 27, 2026 |
| Dec 16, 2025 | SRPT Sarepta Therapeutics, Inc. | SOpen-market sale Common Stock | -13,187 | $22.31 | $294k | 193,300 | Dec 18, 2025 |
| Sep 3, 2025 | SRPT Sarepta Therapeutics, Inc. | AGrant or award Common Stock | +93,875 | $0.00 | $0 | 156,487 | Sep 5, 2025 |
| Sep 3, 2025 | SRPT Sarepta Therapeutics, Inc. | AGrant or award Common Stock | +50,000 | $0.00 | $0 | 206,487 | Sep 5, 2025 |
| Aug 5, 2025 | SRPT Sarepta Therapeutics, Inc. | AGrant or award Performance Stock Unitsderivative | +6,250 | $0.00 | $0 | 6,250 | Aug 6, 2025 |
| Mar 7, 2025 | SRPT Sarepta Therapeutics, Inc. | MOption exercise Common Stock | +5,500 | - | - | 58,277 | Mar 11, 2025 |
| Mar 10, 2025 | SRPT Sarepta Therapeutics, Inc. | FTax withholding Common Stock | -1,051 | $100.13 | $105k | 57,226 | Mar 11, 2025 |
| Mar 10, 2025 | SRPT Sarepta Therapeutics, Inc. | FTax withholding Common Stock | -2,890 | $100.13 | $289k | 54,336 | Mar 11, 2025 |
| Mar 10, 2025 | SRPT Sarepta Therapeutics, Inc. | AGrant or award Common Stock | +8,276 | - | - | 62,612 | Mar 11, 2025 |
| Mar 7, 2025 | SRPT Sarepta Therapeutics, Inc. | MOption exercise Performance Stock Unitsderivative | -5,500 | $0.00 | $0 | 0 | Mar 11, 2025 |
| Mar 10, 2025 | SRPT Sarepta Therapeutics, Inc. | AGrant or award Stock Options (right to buy)derivative | +16,644 | $0.00 | $0 | 16,644 | Mar 11, 2025 |
| Mar 6, 2025 | SRPT Sarepta Therapeutics, Inc. | MOption exercise Common Stock | +17,500 | - | - | 62,456 | Mar 10, 2025 |
| Mar 7, 2025 | SRPT Sarepta Therapeutics, Inc. | FTax withholding Common Stock | -585 | $103.70 | $61k | 61,871 | Mar 10, 2025 |
| Mar 7, 2025 | SRPT Sarepta Therapeutics, Inc. | FTax withholding Common Stock | -9,094 | $103.70 | $943k | 52,777 | Mar 10, 2025 |
| Mar 6, 2025 | SRPT Sarepta Therapeutics, Inc. | MOption exercise Performance Stock Unitsderivative | -17,500 | $0.00 | $0 | 0 | Mar 10, 2025 |
| Mar 4, 2025 | SRPT Sarepta Therapeutics, Inc. | FTax withholding Common Stock | -1,370 | $101.34 | $139k | 44,956 | Mar 6, 2025 |
| Mar 3, 2025 | SRPT Sarepta Therapeutics, Inc. | FTax withholding Common Stock | -557 | $103.77 | $58k | 46,326 | Mar 4, 2025 |
| Feb 11, 2025 | SRPT Sarepta Therapeutics, Inc. | AGrant or award Performance Restricted Stock Unitsderivative | +3,500 | $0.00 | $0 | 17,500 | Feb 13, 2025 |
| Jan 29, 2025 | SRPT Sarepta Therapeutics, Inc. | MOption exercise Common Stock | +14,267 | $12.00 | $171k | 47,963 | Jan 31, 2025 |
| Jan 29, 2025 | SRPT Sarepta Therapeutics, Inc. | MOption exercise Common Stock | +1,533 | $12.00 | $18k | 49,496 | Jan 31, 2025 |
| Jan 29, 2025 | SRPT Sarepta Therapeutics, Inc. | FTax withholding Common Stock | -2,613 | $117.51 | $307k | 46,883 | Jan 31, 2025 |
| Jan 29, 2025 | SRPT Sarepta Therapeutics, Inc. | MOption exercise Stock Option (right to buy)derivative | -14,267 | $0.00 | $0 | 0 | Jan 31, 2025 |
| Jan 29, 2025 | SRPT Sarepta Therapeutics, Inc. | MOption exercise Stock Option (right to buy)derivative | -1,533 | $0.00 | $0 | 0 | Jan 31, 2025 |
| Dec 27, 2024 | SRPT Sarepta Therapeutics, Inc. | GGift Common Stock | -250 | $0.00 | $0 | 33,696 | Dec 30, 2024 |
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.